Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.40 |
| ▸ | CA12 | O43570 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6895304 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL6895301 | 0.81 | SMN1; SMN2 (0.58) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL188811 | 0.80 | SMN1; SMN2 (0.70) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL6894766 | 0.77 | SMN1; SMN2 (0.54) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL856080 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL6446523 | 0.73 | SMN1; SMN2 (0.61) | SMN1; SMN2CA14CA12KMT2AALDH1A1 | |
| SCHEMBL4616218 | 0.71 | SMN1; SMN2 (0.71) | SMN1; SMN2CA14CA12MEN1KMT2A | |
| SCHEMBL204828 | 0.70 | — | — | |
| SCHEMBL135981 | 0.70 | — | — | |
| SCHEMBL135982 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1613606-A4 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMA INC (US) | 2008-12-03 | — | — | EP | disclosed |
| EP-1615897-A4 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | NPS PHARMACUETICALS, INC (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| EP-1613606-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004092121-A2 | METHODS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | TYMP, DPYD, UMPS | SMN1; SMN2 2378/4885CA14 2949/4885CA12 3849/4885 |
| US-20070161792-A1 | Methods for preparing 2,3,5,6-substituted 3h-pyrimidin-4-ones | TYMP, DPYD, DHFR | SMN1; SMN2 455/4885CA14 4515/4885CA12 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.